nodes	percent_of_prediction	percent_of_DWPC	metapath
Bosutinib—P-Glycoprotein Inhibitors—Lopinavir—acquired immunodeficiency syndrome	0.419	0.623	CiPCiCtD
Bosutinib—P-Glycoprotein Inhibitors—Ritonavir—acquired immunodeficiency syndrome	0.254	0.377	CiPCiCtD
Bosutinib—ABCB1—Lopinavir—acquired immunodeficiency syndrome	0.00682	0.0906	CbGbCtD
Bosutinib—ABCB1—Amprenavir—acquired immunodeficiency syndrome	0.00617	0.082	CbGbCtD
Bosutinib—ABCB1—Indinavir—acquired immunodeficiency syndrome	0.00533	0.0707	CbGbCtD
Bosutinib—ABCB1—Nelfinavir—acquired immunodeficiency syndrome	0.00517	0.0687	CbGbCtD
Bosutinib—ABCB1—Saquinavir—acquired immunodeficiency syndrome	0.00468	0.0621	CbGbCtD
Bosutinib—ABCB1—Ritonavir—acquired immunodeficiency syndrome	0.00468	0.0621	CbGbCtD
Bosutinib—ABCB1—Zidovudine—acquired immunodeficiency syndrome	0.00448	0.0596	CbGbCtD
Bosutinib—CYP3A4—Efavirenz—acquired immunodeficiency syndrome	0.00435	0.0578	CbGbCtD
Bosutinib—CYP3A4—Lopinavir—acquired immunodeficiency syndrome	0.00409	0.0543	CbGbCtD
Bosutinib—CYP3A4—Nevirapine—acquired immunodeficiency syndrome	0.00409	0.0543	CbGbCtD
Bosutinib—CYP3A4—Delavirdine—acquired immunodeficiency syndrome	0.0037	0.0491	CbGbCtD
Bosutinib—CYP3A4—Amprenavir—acquired immunodeficiency syndrome	0.0037	0.0491	CbGbCtD
Bosutinib—ABCB1—Lamivudine—acquired immunodeficiency syndrome	0.00347	0.0461	CbGbCtD
Bosutinib—CYP3A4—Indinavir—acquired immunodeficiency syndrome	0.00319	0.0424	CbGbCtD
Bosutinib—CYP3A4—Nelfinavir—acquired immunodeficiency syndrome	0.0031	0.0412	CbGbCtD
Bosutinib—CYP3A4—Saquinavir—acquired immunodeficiency syndrome	0.0028	0.0372	CbGbCtD
Bosutinib—CYP3A4—Ritonavir—acquired immunodeficiency syndrome	0.0028	0.0372	CbGbCtD
Bosutinib—CYP3A4—Zidovudine—acquired immunodeficiency syndrome	0.00269	0.0357	CbGbCtD
Bosutinib—Vandetanib—ALB—acquired immunodeficiency syndrome	0.000231	0.513	CrCbGaD
Bosutinib—Gefitinib—ALB—acquired immunodeficiency syndrome	0.000219	0.487	CrCbGaD
Bosutinib—Immune system disorder—Lamivudine—acquired immunodeficiency syndrome	9.36e-05	0.000928	CcSEcCtD
Bosutinib—Diarrhoea—Didanosine—acquired immunodeficiency syndrome	9.35e-05	0.000927	CcSEcCtD
Bosutinib—Discomfort—Efavirenz—acquired immunodeficiency syndrome	9.34e-05	0.000926	CcSEcCtD
Bosutinib—Mediastinal disorder—Lamivudine—acquired immunodeficiency syndrome	9.34e-05	0.000925	CcSEcCtD
Bosutinib—Skin disorder—Indinavir—acquired immunodeficiency syndrome	9.31e-05	0.000923	CcSEcCtD
Bosutinib—Urticaria—Abacavir—acquired immunodeficiency syndrome	9.28e-05	0.00092	CcSEcCtD
Bosutinib—Cough—Delavirdine—acquired immunodeficiency syndrome	9.27e-05	0.000919	CcSEcCtD
Bosutinib—Dysgeusia—Saquinavir—acquired immunodeficiency syndrome	9.26e-05	0.000918	CcSEcCtD
Bosutinib—Body temperature increased—Abacavir—acquired immunodeficiency syndrome	9.24e-05	0.000916	CcSEcCtD
Bosutinib—Abdominal pain—Abacavir—acquired immunodeficiency syndrome	9.24e-05	0.000916	CcSEcCtD
Bosutinib—Dyspnoea—Zidovudine—acquired immunodeficiency syndrome	9.19e-05	0.000911	CcSEcCtD
Bosutinib—Back pain—Saquinavir—acquired immunodeficiency syndrome	9.14e-05	0.000906	CcSEcCtD
Bosutinib—Ill-defined disorder—Ritonavir—acquired immunodeficiency syndrome	9.11e-05	0.000903	CcSEcCtD
Bosutinib—Anaemia—Ritonavir—acquired immunodeficiency syndrome	9.08e-05	0.0009	CcSEcCtD
Bosutinib—Chest pain—Delavirdine—acquired immunodeficiency syndrome	9.04e-05	0.000896	CcSEcCtD
Bosutinib—Myalgia—Delavirdine—acquired immunodeficiency syndrome	9.04e-05	0.000896	CcSEcCtD
Bosutinib—Arthralgia—Delavirdine—acquired immunodeficiency syndrome	9.04e-05	0.000896	CcSEcCtD
Bosutinib—Malnutrition—Lamivudine—acquired immunodeficiency syndrome	9.02e-05	0.000894	CcSEcCtD
Bosutinib—Decreased appetite—Zidovudine—acquired immunodeficiency syndrome	8.96e-05	0.000888	CcSEcCtD
Bosutinib—Discomfort—Delavirdine—acquired immunodeficiency syndrome	8.93e-05	0.000886	CcSEcCtD
Bosutinib—Nausea—Amprenavir—acquired immunodeficiency syndrome	8.9e-05	0.000882	CcSEcCtD
Bosutinib—Gastrointestinal disorder—Zidovudine—acquired immunodeficiency syndrome	8.9e-05	0.000882	CcSEcCtD
Bosutinib—Fatigue—Zidovudine—acquired immunodeficiency syndrome	8.89e-05	0.000881	CcSEcCtD
Bosutinib—Nervous system disorder—Efavirenz—acquired immunodeficiency syndrome	8.88e-05	0.000881	CcSEcCtD
Bosutinib—Thrombocytopenia—Efavirenz—acquired immunodeficiency syndrome	8.87e-05	0.000879	CcSEcCtD
Bosutinib—Malaise—Ritonavir—acquired immunodeficiency syndrome	8.86e-05	0.000878	CcSEcCtD
Bosutinib—Dysgeusia—Lamivudine—acquired immunodeficiency syndrome	8.83e-05	0.000875	CcSEcCtD
Bosutinib—Pain—Zidovudine—acquired immunodeficiency syndrome	8.82e-05	0.000874	CcSEcCtD
Bosutinib—Asthenia—Nevirapine—acquired immunodeficiency syndrome	8.81e-05	0.000874	CcSEcCtD
Bosutinib—Skin disorder—Efavirenz—acquired immunodeficiency syndrome	8.8e-05	0.000872	CcSEcCtD
Bosutinib—Leukopenia—Ritonavir—acquired immunodeficiency syndrome	8.79e-05	0.000871	CcSEcCtD
Bosutinib—Ill-defined disorder—Saquinavir—acquired immunodeficiency syndrome	8.77e-05	0.000869	CcSEcCtD
Bosutinib—Anaemia—Saquinavir—acquired immunodeficiency syndrome	8.74e-05	0.000866	CcSEcCtD
Bosutinib—Musculoskeletal discomfort—Indinavir—acquired immunodeficiency syndrome	8.73e-05	0.000866	CcSEcCtD
Bosutinib—Back pain—Lamivudine—acquired immunodeficiency syndrome	8.72e-05	0.000865	CcSEcCtD
Bosutinib—Pruritus—Nevirapine—acquired immunodeficiency syndrome	8.69e-05	0.000862	CcSEcCtD
Bosutinib—Vomiting—Didanosine—acquired immunodeficiency syndrome	8.69e-05	0.000861	CcSEcCtD
Bosutinib—Oedema—Delavirdine—acquired immunodeficiency syndrome	8.67e-05	0.000859	CcSEcCtD
Bosutinib—Rash—Didanosine—acquired immunodeficiency syndrome	8.61e-05	0.000854	CcSEcCtD
Bosutinib—Infection—Delavirdine—acquired immunodeficiency syndrome	8.61e-05	0.000854	CcSEcCtD
Bosutinib—Dermatitis—Didanosine—acquired immunodeficiency syndrome	8.61e-05	0.000853	CcSEcCtD
Bosutinib—Cough—Ritonavir—acquired immunodeficiency syndrome	8.57e-05	0.00085	CcSEcCtD
Bosutinib—Headache—Didanosine—acquired immunodeficiency syndrome	8.56e-05	0.000848	CcSEcCtD
Bosutinib—Dyspnoea—Indinavir—acquired immunodeficiency syndrome	8.55e-05	0.000847	CcSEcCtD
Bosutinib—Asthenia—Nelfinavir—acquired immunodeficiency syndrome	8.54e-05	0.000846	CcSEcCtD
Bosutinib—Malaise—Saquinavir—acquired immunodeficiency syndrome	8.52e-05	0.000845	CcSEcCtD
Bosutinib—Asthenia—Stavudine—acquired immunodeficiency syndrome	8.51e-05	0.000844	CcSEcCtD
Bosutinib—Feeling abnormal—Zidovudine—acquired immunodeficiency syndrome	8.49e-05	0.000842	CcSEcCtD
Bosutinib—Thrombocytopenia—Delavirdine—acquired immunodeficiency syndrome	8.49e-05	0.000841	CcSEcCtD
Bosutinib—Leukopenia—Saquinavir—acquired immunodeficiency syndrome	8.46e-05	0.000839	CcSEcCtD
Bosutinib—Gastrointestinal pain—Zidovudine—acquired immunodeficiency syndrome	8.43e-05	0.000836	CcSEcCtD
Bosutinib—Skin disorder—Delavirdine—acquired immunodeficiency syndrome	8.42e-05	0.000835	CcSEcCtD
Bosutinib—Pruritus—Nelfinavir—acquired immunodeficiency syndrome	8.42e-05	0.000834	CcSEcCtD
Bosutinib—Diarrhoea—Nevirapine—acquired immunodeficiency syndrome	8.4e-05	0.000833	CcSEcCtD
Bosutinib—Pruritus—Stavudine—acquired immunodeficiency syndrome	8.39e-05	0.000832	CcSEcCtD
Bosutinib—Asthenia—Abacavir—acquired immunodeficiency syndrome	8.38e-05	0.000831	CcSEcCtD
Bosutinib—Ill-defined disorder—Lamivudine—acquired immunodeficiency syndrome	8.37e-05	0.000829	CcSEcCtD
Bosutinib—Arthralgia—Ritonavir—acquired immunodeficiency syndrome	8.36e-05	0.000829	CcSEcCtD
Bosutinib—Chest pain—Ritonavir—acquired immunodeficiency syndrome	8.36e-05	0.000829	CcSEcCtD
Bosutinib—Myalgia—Ritonavir—acquired immunodeficiency syndrome	8.36e-05	0.000829	CcSEcCtD
Bosutinib—Decreased appetite—Indinavir—acquired immunodeficiency syndrome	8.33e-05	0.000826	CcSEcCtD
Bosutinib—Anaemia—Lamivudine—acquired immunodeficiency syndrome	8.33e-05	0.000826	CcSEcCtD
Bosutinib—Unspecified disorder of skin and subcutaneous tissue—Ritonavir—acquired immunodeficiency syndrome	8.3e-05	0.000823	CcSEcCtD
Bosutinib—Gastrointestinal disorder—Indinavir—acquired immunodeficiency syndrome	8.28e-05	0.000821	CcSEcCtD
Bosutinib—Pruritus—Abacavir—acquired immunodeficiency syndrome	8.27e-05	0.00082	CcSEcCtD
Bosutinib—Fatigue—Indinavir—acquired immunodeficiency syndrome	8.27e-05	0.000819	CcSEcCtD
Bosutinib—Discomfort—Ritonavir—acquired immunodeficiency syndrome	8.26e-05	0.000819	CcSEcCtD
Bosutinib—Musculoskeletal discomfort—Efavirenz—acquired immunodeficiency syndrome	8.25e-05	0.000818	CcSEcCtD
Bosutinib—Cough—Saquinavir—acquired immunodeficiency syndrome	8.25e-05	0.000818	CcSEcCtD
Bosutinib—Pain—Indinavir—acquired immunodeficiency syndrome	8.2e-05	0.000813	CcSEcCtD
Bosutinib—Urticaria—Zidovudine—acquired immunodeficiency syndrome	8.19e-05	0.000812	CcSEcCtD
Bosutinib—Body temperature increased—Zidovudine—acquired immunodeficiency syndrome	8.15e-05	0.000808	CcSEcCtD
Bosutinib—Abdominal pain—Zidovudine—acquired immunodeficiency syndrome	8.15e-05	0.000808	CcSEcCtD
Bosutinib—Diarrhoea—Nelfinavir—acquired immunodeficiency syndrome	8.14e-05	0.000807	CcSEcCtD
Bosutinib—Malaise—Lamivudine—acquired immunodeficiency syndrome	8.13e-05	0.000806	CcSEcCtD
Bosutinib—Diarrhoea—Stavudine—acquired immunodeficiency syndrome	8.12e-05	0.000805	CcSEcCtD
Bosutinib—Nausea—Didanosine—acquired immunodeficiency syndrome	8.11e-05	0.000804	CcSEcCtD
Bosutinib—Dyspnoea—Efavirenz—acquired immunodeficiency syndrome	8.08e-05	0.000801	CcSEcCtD
Bosutinib—Leukopenia—Lamivudine—acquired immunodeficiency syndrome	8.07e-05	0.0008	CcSEcCtD
Bosutinib—Myalgia—Saquinavir—acquired immunodeficiency syndrome	8.05e-05	0.000798	CcSEcCtD
Bosutinib—Arthralgia—Saquinavir—acquired immunodeficiency syndrome	8.05e-05	0.000798	CcSEcCtD
Bosutinib—Chest pain—Saquinavir—acquired immunodeficiency syndrome	8.05e-05	0.000798	CcSEcCtD
Bosutinib—Oedema—Ritonavir—acquired immunodeficiency syndrome	8.01e-05	0.000795	CcSEcCtD
Bosutinib—Diarrhoea—Abacavir—acquired immunodeficiency syndrome	7.99e-05	0.000793	CcSEcCtD
Bosutinib—Unspecified disorder of skin and subcutaneous tissue—Saquinavir—acquired immunodeficiency syndrome	7.99e-05	0.000792	CcSEcCtD
Bosutinib—Discomfort—Saquinavir—acquired immunodeficiency syndrome	7.95e-05	0.000788	CcSEcCtD
Bosutinib—Feeling abnormal—Indinavir—acquired immunodeficiency syndrome	7.9e-05	0.000783	CcSEcCtD
Bosutinib—Musculoskeletal discomfort—Delavirdine—acquired immunodeficiency syndrome	7.9e-05	0.000783	CcSEcCtD
Bosutinib—Decreased appetite—Efavirenz—acquired immunodeficiency syndrome	7.87e-05	0.000781	CcSEcCtD
Bosutinib—Cough—Lamivudine—acquired immunodeficiency syndrome	7.87e-05	0.00078	CcSEcCtD
Bosutinib—Dizziness—Nelfinavir—acquired immunodeficiency syndrome	7.87e-05	0.00078	CcSEcCtD
Bosutinib—Nervous system disorder—Ritonavir—acquired immunodeficiency syndrome	7.86e-05	0.000779	CcSEcCtD
Bosutinib—Thrombocytopenia—Ritonavir—acquired immunodeficiency syndrome	7.85e-05	0.000778	CcSEcCtD
Bosutinib—Dizziness—Stavudine—acquired immunodeficiency syndrome	7.84e-05	0.000778	CcSEcCtD
Bosutinib—Gastrointestinal pain—Indinavir—acquired immunodeficiency syndrome	7.84e-05	0.000777	CcSEcCtD
Bosutinib—Gastrointestinal disorder—Efavirenz—acquired immunodeficiency syndrome	7.82e-05	0.000775	CcSEcCtD
Bosutinib—Vomiting—Nevirapine—acquired immunodeficiency syndrome	7.81e-05	0.000774	CcSEcCtD
Bosutinib—Fatigue—Efavirenz—acquired immunodeficiency syndrome	7.81e-05	0.000774	CcSEcCtD
Bosutinib—Skin disorder—Ritonavir—acquired immunodeficiency syndrome	7.78e-05	0.000772	CcSEcCtD
Bosutinib—Pain—Efavirenz—acquired immunodeficiency syndrome	7.75e-05	0.000768	CcSEcCtD
Bosutinib—Rash—Nevirapine—acquired immunodeficiency syndrome	7.75e-05	0.000768	CcSEcCtD
Bosutinib—Dermatitis—Nevirapine—acquired immunodeficiency syndrome	7.74e-05	0.000767	CcSEcCtD
Bosutinib—Dyspnoea—Delavirdine—acquired immunodeficiency syndrome	7.73e-05	0.000766	CcSEcCtD
Bosutinib—Dizziness—Abacavir—acquired immunodeficiency syndrome	7.73e-05	0.000766	CcSEcCtD
Bosutinib—Oedema—Saquinavir—acquired immunodeficiency syndrome	7.71e-05	0.000765	CcSEcCtD
Bosutinib—Headache—Nevirapine—acquired immunodeficiency syndrome	7.7e-05	0.000763	CcSEcCtD
Bosutinib—Chest pain—Lamivudine—acquired immunodeficiency syndrome	7.68e-05	0.000761	CcSEcCtD
Bosutinib—Arthralgia—Lamivudine—acquired immunodeficiency syndrome	7.68e-05	0.000761	CcSEcCtD
Bosutinib—Myalgia—Lamivudine—acquired immunodeficiency syndrome	7.68e-05	0.000761	CcSEcCtD
Bosutinib—Infection—Saquinavir—acquired immunodeficiency syndrome	7.66e-05	0.00076	CcSEcCtD
Bosutinib—Unspecified disorder of skin and subcutaneous tissue—Lamivudine—acquired immunodeficiency syndrome	7.62e-05	0.000756	CcSEcCtD
Bosutinib—Urticaria—Indinavir—acquired immunodeficiency syndrome	7.62e-05	0.000755	CcSEcCtD
Bosutinib—Discomfort—Lamivudine—acquired immunodeficiency syndrome	7.58e-05	0.000752	CcSEcCtD
Bosutinib—Abdominal pain—Indinavir—acquired immunodeficiency syndrome	7.58e-05	0.000751	CcSEcCtD
Bosutinib—Body temperature increased—Indinavir—acquired immunodeficiency syndrome	7.58e-05	0.000751	CcSEcCtD
Bosutinib—Nervous system disorder—Saquinavir—acquired immunodeficiency syndrome	7.56e-05	0.00075	CcSEcCtD
Bosutinib—Vomiting—Nelfinavir—acquired immunodeficiency syndrome	7.56e-05	0.00075	CcSEcCtD
Bosutinib—SLK—vagina—acquired immunodeficiency syndrome	7.56e-05	0.000904	CbGeAlD
Bosutinib—Thrombocytopenia—Saquinavir—acquired immunodeficiency syndrome	7.55e-05	0.000749	CcSEcCtD
Bosutinib—PTK2B—central nervous system—acquired immunodeficiency syndrome	7.55e-05	0.000903	CbGeAlD
Bosutinib—BTK—brain—acquired immunodeficiency syndrome	7.54e-05	0.000902	CbGeAlD
Bosutinib—Vomiting—Stavudine—acquired immunodeficiency syndrome	7.54e-05	0.000748	CcSEcCtD
Bosutinib—Decreased appetite—Delavirdine—acquired immunodeficiency syndrome	7.53e-05	0.000747	CcSEcCtD
Bosutinib—STK10—lymphoid tissue—acquired immunodeficiency syndrome	7.53e-05	0.000901	CbGeAlD
Bosutinib—EPHA4—nervous system—acquired immunodeficiency syndrome	7.52e-05	0.000899	CbGeAlD
Bosutinib—YES1—digestive system—acquired immunodeficiency syndrome	7.51e-05	0.000898	CbGeAlD
Bosutinib—TAOK3—lymphoid tissue—acquired immunodeficiency syndrome	7.5e-05	0.000897	CbGeAlD
Bosutinib—Rash—Nelfinavir—acquired immunodeficiency syndrome	7.5e-05	0.000744	CcSEcCtD
Bosutinib—EPHB4—vagina—acquired immunodeficiency syndrome	7.5e-05	0.000897	CbGeAlD
Bosutinib—RPS6KB1—lung—acquired immunodeficiency syndrome	7.5e-05	0.000897	CbGeAlD
Bosutinib—Dermatitis—Nelfinavir—acquired immunodeficiency syndrome	7.49e-05	0.000743	CcSEcCtD
Bosutinib—MAP3K3—bone marrow—acquired immunodeficiency syndrome	7.49e-05	0.000896	CbGeAlD
Bosutinib—MAP4K5—bone marrow—acquired immunodeficiency syndrome	7.49e-05	0.000896	CbGeAlD
Bosutinib—Skin disorder—Saquinavir—acquired immunodeficiency syndrome	7.49e-05	0.000743	CcSEcCtD
Bosutinib—Gastrointestinal disorder—Delavirdine—acquired immunodeficiency syndrome	7.48e-05	0.000742	CcSEcCtD
Bosutinib—Rash—Stavudine—acquired immunodeficiency syndrome	7.48e-05	0.000741	CcSEcCtD
Bosutinib—FER—lymph node—acquired immunodeficiency syndrome	7.48e-05	0.000894	CbGeAlD
Bosutinib—ALK—lymph node—acquired immunodeficiency syndrome	7.48e-05	0.000894	CbGeAlD
Bosutinib—Fatigue—Delavirdine—acquired immunodeficiency syndrome	7.47e-05	0.000741	CcSEcCtD
Bosutinib—Dermatitis—Stavudine—acquired immunodeficiency syndrome	7.47e-05	0.000741	CcSEcCtD
Bosutinib—Feeling abnormal—Efavirenz—acquired immunodeficiency syndrome	7.46e-05	0.00074	CcSEcCtD
Bosutinib—MAP3K3—spinal cord—acquired immunodeficiency syndrome	7.46e-05	0.000892	CbGeAlD
Bosutinib—MAP4K5—spinal cord—acquired immunodeficiency syndrome	7.46e-05	0.000892	CbGeAlD
Bosutinib—Headache—Nelfinavir—acquired immunodeficiency syndrome	7.45e-05	0.000739	CcSEcCtD
Bosutinib—FGR—lung—acquired immunodeficiency syndrome	7.45e-05	0.000891	CbGeAlD
Bosutinib—LCK—lung—acquired immunodeficiency syndrome	7.45e-05	0.000891	CbGeAlD
Bosutinib—ERBB3—nervous system—acquired immunodeficiency syndrome	7.44e-05	0.00089	CbGeAlD
Bosutinib—STK10—digestive system—acquired immunodeficiency syndrome	7.44e-05	0.00089	CbGeAlD
Bosutinib—TNK2—brain—acquired immunodeficiency syndrome	7.43e-05	0.000889	CbGeAlD
Bosutinib—Headache—Stavudine—acquired immunodeficiency syndrome	7.43e-05	0.000737	CcSEcCtD
Bosutinib—Vomiting—Abacavir—acquired immunodeficiency syndrome	7.43e-05	0.000736	CcSEcCtD
Bosutinib—CSNK1E—central nervous system—acquired immunodeficiency syndrome	7.42e-05	0.000888	CbGeAlD
Bosutinib—MAP2K2—nervous system—acquired immunodeficiency syndrome	7.42e-05	0.000888	CbGeAlD
Bosutinib—ULK3—nervous system—acquired immunodeficiency syndrome	7.42e-05	0.000888	CbGeAlD
Bosutinib—AXL—lung—acquired immunodeficiency syndrome	7.42e-05	0.000888	CbGeAlD
Bosutinib—Pain—Delavirdine—acquired immunodeficiency syndrome	7.41e-05	0.000735	CcSEcCtD
Bosutinib—TAOK3—digestive system—acquired immunodeficiency syndrome	7.41e-05	0.000886	CbGeAlD
Bosutinib—Gastrointestinal pain—Efavirenz—acquired immunodeficiency syndrome	7.41e-05	0.000734	CcSEcCtD
Bosutinib—Asthenia—Zidovudine—acquired immunodeficiency syndrome	7.4e-05	0.000733	CcSEcCtD
Bosutinib—MAP3K2—nervous system—acquired immunodeficiency syndrome	7.37e-05	0.000881	CbGeAlD
Bosutinib—Rash—Abacavir—acquired immunodeficiency syndrome	7.37e-05	0.00073	CcSEcCtD
Bosutinib—Dermatitis—Abacavir—acquired immunodeficiency syndrome	7.36e-05	0.00073	CcSEcCtD
Bosutinib—Anaphylactic shock—Lamivudine—acquired immunodeficiency syndrome	7.36e-05	0.00073	CcSEcCtD
Bosutinib—Oedema—Lamivudine—acquired immunodeficiency syndrome	7.36e-05	0.00073	CcSEcCtD
Bosutinib—EPHA2—vagina—acquired immunodeficiency syndrome	7.36e-05	0.00088	CbGeAlD
Bosutinib—FYN—vagina—acquired immunodeficiency syndrome	7.35e-05	0.000879	CbGeAlD
Bosutinib—MAP4K2—brain—acquired immunodeficiency syndrome	7.33e-05	0.000877	CbGeAlD
Bosutinib—MAP4K1—lymph node—acquired immunodeficiency syndrome	7.32e-05	0.000876	CbGeAlD
Bosutinib—Headache—Abacavir—acquired immunodeficiency syndrome	7.32e-05	0.000726	CcSEcCtD
Bosutinib—SRC—lymphoid tissue—acquired immunodeficiency syndrome	7.31e-05	0.000874	CbGeAlD
Bosutinib—Infection—Lamivudine—acquired immunodeficiency syndrome	7.31e-05	0.000725	CcSEcCtD
Bosutinib—SIK1—central nervous system—acquired immunodeficiency syndrome	7.31e-05	0.000874	CbGeAlD
Bosutinib—IRAK4—central nervous system—acquired immunodeficiency syndrome	7.31e-05	0.000874	CbGeAlD
Bosutinib—Musculoskeletal discomfort—Ritonavir—acquired immunodeficiency syndrome	7.3e-05	0.000724	CcSEcCtD
Bosutinib—ABL1—retina—acquired immunodeficiency syndrome	7.3e-05	0.000873	CbGeAlD
Bosutinib—Nausea—Nevirapine—acquired immunodeficiency syndrome	7.3e-05	0.000723	CcSEcCtD
Bosutinib—Pruritus—Zidovudine—acquired immunodeficiency syndrome	7.29e-05	0.000723	CcSEcCtD
Bosutinib—BTK—lymph node—acquired immunodeficiency syndrome	7.29e-05	0.000872	CbGeAlD
Bosutinib—EPHA4—central nervous system—acquired immunodeficiency syndrome	7.24e-05	0.000865	CbGeAlD
Bosutinib—ERBB4—brain—acquired immunodeficiency syndrome	7.23e-05	0.000865	CbGeAlD
Bosutinib—STK3—brain—acquired immunodeficiency syndrome	7.23e-05	0.000865	CbGeAlD
Bosutinib—SRC—digestive system—acquired immunodeficiency syndrome	7.22e-05	0.000864	CbGeAlD
Bosutinib—PTK2—nervous system—acquired immunodeficiency syndrome	7.22e-05	0.000863	CbGeAlD
Bosutinib—TBK1—nervous system—acquired immunodeficiency syndrome	7.22e-05	0.000863	CbGeAlD
Bosutinib—Nervous system disorder—Lamivudine—acquired immunodeficiency syndrome	7.22e-05	0.000715	CcSEcCtD
Bosutinib—Thrombocytopenia—Lamivudine—acquired immunodeficiency syndrome	7.21e-05	0.000714	CcSEcCtD
Bosutinib—Urticaria—Efavirenz—acquired immunodeficiency syndrome	7.2e-05	0.000713	CcSEcCtD
Bosutinib—PDGFRB—skin of body—acquired immunodeficiency syndrome	7.19e-05	0.00086	CbGeAlD
Bosutinib—TNK2—lymph node—acquired immunodeficiency syndrome	7.18e-05	0.000859	CbGeAlD
Bosutinib—MAP4K5—vagina—acquired immunodeficiency syndrome	7.18e-05	0.000859	CbGeAlD
Bosutinib—MAP3K3—vagina—acquired immunodeficiency syndrome	7.18e-05	0.000859	CbGeAlD
Bosutinib—ERBB3—central nervous system—acquired immunodeficiency syndrome	7.16e-05	0.000857	CbGeAlD
Bosutinib—Body temperature increased—Efavirenz—acquired immunodeficiency syndrome	7.16e-05	0.00071	CcSEcCtD
Bosutinib—Abdominal pain—Efavirenz—acquired immunodeficiency syndrome	7.16e-05	0.00071	CcSEcCtD
Bosutinib—YES1—blood—acquired immunodeficiency syndrome	7.15e-05	0.000855	CbGeAlD
Bosutinib—Skin disorder—Lamivudine—acquired immunodeficiency syndrome	7.15e-05	0.000709	CcSEcCtD
Bosutinib—ULK3—central nervous system—acquired immunodeficiency syndrome	7.15e-05	0.000855	CbGeAlD
Bosutinib—MAP2K2—central nervous system—acquired immunodeficiency syndrome	7.15e-05	0.000855	CbGeAlD
Bosutinib—Dyspnoea—Ritonavir—acquired immunodeficiency syndrome	7.15e-05	0.000708	CcSEcCtD
Bosutinib—SLK—lung—acquired immunodeficiency syndrome	7.15e-05	0.000855	CbGeAlD
Bosutinib—Feeling abnormal—Delavirdine—acquired immunodeficiency syndrome	7.14e-05	0.000708	CcSEcCtD
Bosutinib—ROCK1—brain—acquired immunodeficiency syndrome	7.14e-05	0.000854	CbGeAlD
Bosutinib—MAP3K2—central nervous system—acquired immunodeficiency syndrome	7.1e-05	0.000849	CbGeAlD
Bosutinib—EPHB4—lung—acquired immunodeficiency syndrome	7.09e-05	0.000848	CbGeAlD
Bosutinib—STK10—blood—acquired immunodeficiency syndrome	7.09e-05	0.000848	CbGeAlD
Bosutinib—Gastrointestinal pain—Delavirdine—acquired immunodeficiency syndrome	7.09e-05	0.000703	CcSEcCtD
Bosutinib—MAP4K2—lymph node—acquired immunodeficiency syndrome	7.08e-05	0.000847	CbGeAlD
Bosutinib—Nausea—Nelfinavir—acquired immunodeficiency syndrome	7.07e-05	0.000701	CcSEcCtD
Bosutinib—TAOK3—blood—acquired immunodeficiency syndrome	7.06e-05	0.000844	CbGeAlD
Bosutinib—Diarrhoea—Zidovudine—acquired immunodeficiency syndrome	7.05e-05	0.000699	CcSEcCtD
Bosutinib—Nausea—Stavudine—acquired immunodeficiency syndrome	7.04e-05	0.000698	CcSEcCtD
Bosutinib—Musculoskeletal discomfort—Saquinavir—acquired immunodeficiency syndrome	7.03e-05	0.000697	CcSEcCtD
Bosutinib—STK3—lymph node—acquired immunodeficiency syndrome	6.99e-05	0.000836	CbGeAlD
Bosutinib—Decreased appetite—Ritonavir—acquired immunodeficiency syndrome	6.97e-05	0.000691	CcSEcCtD
Bosutinib—EPHA2—lung—acquired immunodeficiency syndrome	6.96e-05	0.000832	CbGeAlD
Bosutinib—TBK1—central nervous system—acquired immunodeficiency syndrome	6.95e-05	0.000831	CbGeAlD
Bosutinib—PTK2—central nervous system—acquired immunodeficiency syndrome	6.95e-05	0.000831	CbGeAlD
Bosutinib—FYN—lung—acquired immunodeficiency syndrome	6.95e-05	0.000831	CbGeAlD
Bosutinib—RPS6KB1—nervous system—acquired immunodeficiency syndrome	6.94e-05	0.00083	CbGeAlD
Bosutinib—Nausea—Abacavir—acquired immunodeficiency syndrome	6.94e-05	0.000688	CcSEcCtD
Bosutinib—BMPR2—brain—acquired immunodeficiency syndrome	6.93e-05	0.000829	CbGeAlD
Bosutinib—YES1—bone marrow—acquired immunodeficiency syndrome	6.92e-05	0.000828	CbGeAlD
Bosutinib—Gastrointestinal disorder—Ritonavir—acquired immunodeficiency syndrome	6.92e-05	0.000686	CcSEcCtD
Bosutinib—Fatigue—Ritonavir—acquired immunodeficiency syndrome	6.91e-05	0.000685	CcSEcCtD
Bosutinib—FGR—nervous system—acquired immunodeficiency syndrome	6.9e-05	0.000825	CbGeAlD
Bosutinib—YES1—spinal cord—acquired immunodeficiency syndrome	6.89e-05	0.000824	CbGeAlD
Bosutinib—Urticaria—Delavirdine—acquired immunodeficiency syndrome	6.89e-05	0.000683	CcSEcCtD
Bosutinib—SRC—blood—acquired immunodeficiency syndrome	6.88e-05	0.000823	CbGeAlD
Bosutinib—Asthenia—Indinavir—acquired immunodeficiency syndrome	6.88e-05	0.000682	CcSEcCtD
Bosutinib—EPHB3—brain—acquired immunodeficiency syndrome	6.88e-05	0.000823	CbGeAlD
Bosutinib—STK36—brain—acquired immunodeficiency syndrome	6.88e-05	0.000823	CbGeAlD
Bosutinib—Dyspnoea—Saquinavir—acquired immunodeficiency syndrome	6.88e-05	0.000682	CcSEcCtD
Bosutinib—AXL—nervous system—acquired immunodeficiency syndrome	6.87e-05	0.000822	CbGeAlD
Bosutinib—STK10—bone marrow—acquired immunodeficiency syndrome	6.86e-05	0.00082	CbGeAlD
Bosutinib—Pain—Ritonavir—acquired immunodeficiency syndrome	6.85e-05	0.000679	CcSEcCtD
Bosutinib—Body temperature increased—Delavirdine—acquired immunodeficiency syndrome	6.85e-05	0.000679	CcSEcCtD
Bosutinib—Abdominal pain—Delavirdine—acquired immunodeficiency syndrome	6.85e-05	0.000679	CcSEcCtD
Bosutinib—TAOK3—bone marrow—acquired immunodeficiency syndrome	6.83e-05	0.000817	CbGeAlD
Bosutinib—Dizziness—Zidovudine—acquired immunodeficiency syndrome	6.82e-05	0.000676	CcSEcCtD
Bosutinib—TAOK3—spinal cord—acquired immunodeficiency syndrome	6.8e-05	0.000814	CbGeAlD
Bosutinib—MERTK—brain—acquired immunodeficiency syndrome	6.8e-05	0.000813	CbGeAlD
Bosutinib—MAP4K5—lung—acquired immunodeficiency syndrome	6.79e-05	0.000812	CbGeAlD
Bosutinib—MAP3K3—lung—acquired immunodeficiency syndrome	6.79e-05	0.000812	CbGeAlD
Bosutinib—Pruritus—Indinavir—acquired immunodeficiency syndrome	6.78e-05	0.000672	CcSEcCtD
Bosutinib—Decreased appetite—Saquinavir—acquired immunodeficiency syndrome	6.71e-05	0.000665	CcSEcCtD
Bosutinib—Musculoskeletal discomfort—Lamivudine—acquired immunodeficiency syndrome	6.7e-05	0.000665	CcSEcCtD
Bosutinib—BMPR2—lymph node—acquired immunodeficiency syndrome	6.7e-05	0.000801	CbGeAlD
Bosutinib—RPS6KB1—central nervous system—acquired immunodeficiency syndrome	6.69e-05	0.0008	CbGeAlD
Bosutinib—MAP4K4—brain—acquired immunodeficiency syndrome	6.67e-05	0.000798	CbGeAlD
Bosutinib—Gastrointestinal disorder—Saquinavir—acquired immunodeficiency syndrome	6.66e-05	0.00066	CcSEcCtD
Bosutinib—Fatigue—Saquinavir—acquired immunodeficiency syndrome	6.65e-05	0.000659	CcSEcCtD
Bosutinib—STK36—lymph node—acquired immunodeficiency syndrome	6.65e-05	0.000795	CbGeAlD
Bosutinib—EPHB3—lymph node—acquired immunodeficiency syndrome	6.65e-05	0.000795	CbGeAlD
Bosutinib—FGR—central nervous system—acquired immunodeficiency syndrome	6.64e-05	0.000795	CbGeAlD
Bosutinib—YES1—vagina—acquired immunodeficiency syndrome	6.63e-05	0.000793	CbGeAlD
Bosutinib—SRC—spinal cord—acquired immunodeficiency syndrome	6.63e-05	0.000793	CbGeAlD
Bosutinib—NUAK2—brain—acquired immunodeficiency syndrome	6.63e-05	0.000792	CbGeAlD
Bosutinib—BCR—brain—acquired immunodeficiency syndrome	6.63e-05	0.000792	CbGeAlD
Bosutinib—AXL—central nervous system—acquired immunodeficiency syndrome	6.62e-05	0.000791	CbGeAlD
Bosutinib—Feeling abnormal—Ritonavir—acquired immunodeficiency syndrome	6.6e-05	0.000655	CcSEcCtD
Bosutinib—Pain—Saquinavir—acquired immunodeficiency syndrome	6.6e-05	0.000654	CcSEcCtD
Bosutinib—MAP3K12—brain—acquired immunodeficiency syndrome	6.58e-05	0.000787	CbGeAlD
Bosutinib—STK10—vagina—acquired immunodeficiency syndrome	6.57e-05	0.000786	CbGeAlD
Bosutinib—MERTK—lymph node—acquired immunodeficiency syndrome	6.57e-05	0.000786	CbGeAlD
Bosutinib—CSF1R—lymphoid tissue—acquired immunodeficiency syndrome	6.56e-05	0.000785	CbGeAlD
Bosutinib—Dyspnoea—Lamivudine—acquired immunodeficiency syndrome	6.56e-05	0.00065	CcSEcCtD
Bosutinib—Diarrhoea—Indinavir—acquired immunodeficiency syndrome	6.56e-05	0.00065	CcSEcCtD
Bosutinib—Vomiting—Zidovudine—acquired immunodeficiency syndrome	6.55e-05	0.00065	CcSEcCtD
Bosutinib—Gastrointestinal pain—Ritonavir—acquired immunodeficiency syndrome	6.55e-05	0.00065	CcSEcCtD
Bosutinib—TAOK3—vagina—acquired immunodeficiency syndrome	6.54e-05	0.000783	CbGeAlD
Bosutinib—Rash—Zidovudine—acquired immunodeficiency syndrome	6.5e-05	0.000644	CcSEcCtD
Bosutinib—Asthenia—Efavirenz—acquired immunodeficiency syndrome	6.5e-05	0.000644	CcSEcCtD
Bosutinib—Dermatitis—Zidovudine—acquired immunodeficiency syndrome	6.49e-05	0.000644	CcSEcCtD
Bosutinib—CSF1R—digestive system—acquired immunodeficiency syndrome	6.48e-05	0.000775	CbGeAlD
Bosutinib—Headache—Zidovudine—acquired immunodeficiency syndrome	6.46e-05	0.00064	CcSEcCtD
Bosutinib—MAP4K4—lymph node—acquired immunodeficiency syndrome	6.45e-05	0.000771	CbGeAlD
Bosutinib—MAP2K1—brain—acquired immunodeficiency syndrome	6.45e-05	0.000771	CbGeAlD
Bosutinib—STK35—brain—acquired immunodeficiency syndrome	6.45e-05	0.000771	CbGeAlD
Bosutinib—EPHA2—nervous system—acquired immunodeficiency syndrome	6.44e-05	0.000771	CbGeAlD
Bosutinib—FYN—nervous system—acquired immunodeficiency syndrome	6.43e-05	0.000769	CbGeAlD
Bosutinib—Pruritus—Efavirenz—acquired immunodeficiency syndrome	6.41e-05	0.000635	CcSEcCtD
Bosutinib—ABL1—skin of body—acquired immunodeficiency syndrome	6.41e-05	0.000766	CbGeAlD
Bosutinib—CSK—brain—acquired immunodeficiency syndrome	6.4e-05	0.000766	CbGeAlD
Bosutinib—BCR—lymph node—acquired immunodeficiency syndrome	6.4e-05	0.000766	CbGeAlD
Bosutinib—NUAK2—lymph node—acquired immunodeficiency syndrome	6.4e-05	0.000766	CbGeAlD
Bosutinib—Decreased appetite—Lamivudine—acquired immunodeficiency syndrome	6.4e-05	0.000634	CcSEcCtD
Bosutinib—Urticaria—Ritonavir—acquired immunodeficiency syndrome	6.37e-05	0.000631	CcSEcCtD
Bosutinib—CSNK1A1—brain—acquired immunodeficiency syndrome	6.36e-05	0.000761	CbGeAlD
Bosutinib—Feeling abnormal—Saquinavir—acquired immunodeficiency syndrome	6.36e-05	0.00063	CcSEcCtD
Bosutinib—MAP3K12—lymph node—acquired immunodeficiency syndrome	6.36e-05	0.00076	CbGeAlD
Bosutinib—Gastrointestinal disorder—Lamivudine—acquired immunodeficiency syndrome	6.35e-05	0.00063	CcSEcCtD
Bosutinib—Fatigue—Lamivudine—acquired immunodeficiency syndrome	6.34e-05	0.000629	CcSEcCtD
Bosutinib—Dizziness—Indinavir—acquired immunodeficiency syndrome	6.34e-05	0.000629	CcSEcCtD
Bosutinib—Abdominal pain—Ritonavir—acquired immunodeficiency syndrome	6.34e-05	0.000628	CcSEcCtD
Bosutinib—Body temperature increased—Ritonavir—acquired immunodeficiency syndrome	6.34e-05	0.000628	CcSEcCtD
Bosutinib—MAP2K5—blood—acquired immunodeficiency syndrome	6.33e-05	0.000757	CbGeAlD
Bosutinib—HCK—brain—acquired immunodeficiency syndrome	6.32e-05	0.000756	CbGeAlD
Bosutinib—CLK1—brain—acquired immunodeficiency syndrome	6.32e-05	0.000756	CbGeAlD
Bosutinib—Gastrointestinal pain—Saquinavir—acquired immunodeficiency syndrome	6.31e-05	0.000625	CcSEcCtD
Bosutinib—Pain—Lamivudine—acquired immunodeficiency syndrome	6.29e-05	0.000624	CcSEcCtD
Bosutinib—MAP3K3—nervous system—acquired immunodeficiency syndrome	6.29e-05	0.000752	CbGeAlD
Bosutinib—MAP4K5—nervous system—acquired immunodeficiency syndrome	6.29e-05	0.000752	CbGeAlD
Bosutinib—ABL2—brain—acquired immunodeficiency syndrome	6.28e-05	0.000751	CbGeAlD
Bosutinib—YES1—lung—acquired immunodeficiency syndrome	6.27e-05	0.00075	CbGeAlD
Bosutinib—MAP2K1—lymph node—acquired immunodeficiency syndrome	6.23e-05	0.000745	CbGeAlD
Bosutinib—STK35—lymph node—acquired immunodeficiency syndrome	6.23e-05	0.000745	CbGeAlD
Bosutinib—Asthenia—Delavirdine—acquired immunodeficiency syndrome	6.22e-05	0.000616	CcSEcCtD
Bosutinib—STK10—lung—acquired immunodeficiency syndrome	6.21e-05	0.000743	CbGeAlD
Bosutinib—EPHA2—central nervous system—acquired immunodeficiency syndrome	6.2e-05	0.000742	CbGeAlD
Bosutinib—BMP2K—brain—acquired immunodeficiency syndrome	6.2e-05	0.000742	CbGeAlD
Bosutinib—CAMK2G—brain—acquired immunodeficiency syndrome	6.2e-05	0.000742	CbGeAlD
Bosutinib—Diarrhoea—Efavirenz—acquired immunodeficiency syndrome	6.2e-05	0.000614	CcSEcCtD
Bosutinib—FYN—central nervous system—acquired immunodeficiency syndrome	6.19e-05	0.000741	CbGeAlD
Bosutinib—TAOK3—lung—acquired immunodeficiency syndrome	6.19e-05	0.00074	CbGeAlD
Bosutinib—CSK—lymph node—acquired immunodeficiency syndrome	6.19e-05	0.00074	CbGeAlD
Bosutinib—CSF1R—blood—acquired immunodeficiency syndrome	6.18e-05	0.000739	CbGeAlD
Bosutinib—LRRK2—brain—acquired immunodeficiency syndrome	6.15e-05	0.000735	CbGeAlD
Bosutinib—CSNK1A1—lymph node—acquired immunodeficiency syndrome	6.15e-05	0.000735	CbGeAlD
Bosutinib—Pruritus—Delavirdine—acquired immunodeficiency syndrome	6.13e-05	0.000608	CcSEcCtD
Bosutinib—EGFR—brain—acquired immunodeficiency syndrome	6.13e-05	0.000733	CbGeAlD
Bosutinib—Urticaria—Saquinavir—acquired immunodeficiency syndrome	6.13e-05	0.000608	CcSEcCtD
Bosutinib—Nausea—Zidovudine—acquired immunodeficiency syndrome	6.12e-05	0.000607	CcSEcCtD
Bosutinib—HCK—lymph node—acquired immunodeficiency syndrome	6.11e-05	0.00073	CbGeAlD
Bosutinib—CLK1—lymph node—acquired immunodeficiency syndrome	6.11e-05	0.00073	CbGeAlD
Bosutinib—Body temperature increased—Saquinavir—acquired immunodeficiency syndrome	6.1e-05	0.000605	CcSEcCtD
Bosutinib—Abdominal pain—Saquinavir—acquired immunodeficiency syndrome	6.1e-05	0.000605	CcSEcCtD
Bosutinib—MAP2K5—spinal cord—acquired immunodeficiency syndrome	6.1e-05	0.000729	CbGeAlD
Bosutinib—Vomiting—Indinavir—acquired immunodeficiency syndrome	6.1e-05	0.000604	CcSEcCtD
Bosutinib—ABL2—lymph node—acquired immunodeficiency syndrome	6.07e-05	0.000726	CbGeAlD
Bosutinib—Feeling abnormal—Lamivudine—acquired immunodeficiency syndrome	6.06e-05	0.000601	CcSEcCtD
Bosutinib—MAP4K5—central nervous system—acquired immunodeficiency syndrome	6.05e-05	0.000724	CbGeAlD
Bosutinib—MAP3K3—central nervous system—acquired immunodeficiency syndrome	6.05e-05	0.000724	CbGeAlD
Bosutinib—Rash—Indinavir—acquired immunodeficiency syndrome	6.04e-05	0.000599	CcSEcCtD
Bosutinib—Dermatitis—Indinavir—acquired immunodeficiency syndrome	6.04e-05	0.000599	CcSEcCtD
Bosutinib—SRC—lung—acquired immunodeficiency syndrome	6.03e-05	0.000721	CbGeAlD
Bosutinib—Gastrointestinal pain—Lamivudine—acquired immunodeficiency syndrome	6.02e-05	0.000597	CcSEcCtD
Bosutinib—Headache—Indinavir—acquired immunodeficiency syndrome	6.01e-05	0.000595	CcSEcCtD
Bosutinib—BMP2K—lymph node—acquired immunodeficiency syndrome	5.99e-05	0.000717	CbGeAlD
Bosutinib—CAMK2G—lymph node—acquired immunodeficiency syndrome	5.99e-05	0.000717	CbGeAlD
Bosutinib—PTK2B—brain—acquired immunodeficiency syndrome	5.99e-05	0.000717	CbGeAlD
Bosutinib—Dizziness—Efavirenz—acquired immunodeficiency syndrome	5.99e-05	0.000594	CcSEcCtD
Bosutinib—CSF1R—bone marrow—acquired immunodeficiency syndrome	5.98e-05	0.000715	CbGeAlD
Bosutinib—CSF1R—spinal cord—acquired immunodeficiency syndrome	5.95e-05	0.000712	CbGeAlD
Bosutinib—LRRK2—lymph node—acquired immunodeficiency syndrome	5.94e-05	0.000711	CbGeAlD
Bosutinib—Diarrhoea—Delavirdine—acquired immunodeficiency syndrome	5.93e-05	0.000588	CcSEcCtD
Bosutinib—EGFR—lymph node—acquired immunodeficiency syndrome	5.92e-05	0.000708	CbGeAlD
Bosutinib—CSNK1E—brain—acquired immunodeficiency syndrome	5.89e-05	0.000705	CbGeAlD
Bosutinib—MAP2K5—vagina—acquired immunodeficiency syndrome	5.87e-05	0.000702	CbGeAlD
Bosutinib—CYP3A4—blood plasma—acquired immunodeficiency syndrome	5.86e-05	0.0007	CbGeAlD
Bosutinib—Urticaria—Lamivudine—acquired immunodeficiency syndrome	5.85e-05	0.00058	CcSEcCtD
Bosutinib—PDGFRB—lymphoid tissue—acquired immunodeficiency syndrome	5.82e-05	0.000696	CbGeAlD
Bosutinib—Abdominal pain—Lamivudine—acquired immunodeficiency syndrome	5.82e-05	0.000577	CcSEcCtD
Bosutinib—Body temperature increased—Lamivudine—acquired immunodeficiency syndrome	5.82e-05	0.000577	CcSEcCtD
Bosutinib—YES1—nervous system—acquired immunodeficiency syndrome	5.81e-05	0.000694	CbGeAlD
Bosutinib—SIK1—brain—acquired immunodeficiency syndrome	5.8e-05	0.000694	CbGeAlD
Bosutinib—IRAK4—brain—acquired immunodeficiency syndrome	5.8e-05	0.000694	CbGeAlD
Bosutinib—PTK2B—lymph node—acquired immunodeficiency syndrome	5.79e-05	0.000692	CbGeAlD
Bosutinib—Vomiting—Efavirenz—acquired immunodeficiency syndrome	5.76e-05	0.000571	CcSEcCtD
Bosutinib—STK10—nervous system—acquired immunodeficiency syndrome	5.75e-05	0.000688	CbGeAlD
Bosutinib—PDGFRB—digestive system—acquired immunodeficiency syndrome	5.75e-05	0.000688	CbGeAlD
Bosutinib—Asthenia—Ritonavir—acquired immunodeficiency syndrome	5.75e-05	0.00057	CcSEcCtD
Bosutinib—EPHA4—brain—acquired immunodeficiency syndrome	5.74e-05	0.000687	CbGeAlD
Bosutinib—TAOK3—nervous system—acquired immunodeficiency syndrome	5.73e-05	0.000685	CbGeAlD
Bosutinib—Dizziness—Delavirdine—acquired immunodeficiency syndrome	5.73e-05	0.000568	CcSEcCtD
Bosutinib—CSF1R—vagina—acquired immunodeficiency syndrome	5.73e-05	0.000685	CbGeAlD
Bosutinib—Rash—Efavirenz—acquired immunodeficiency syndrome	5.71e-05	0.000566	CcSEcCtD
Bosutinib—Dermatitis—Efavirenz—acquired immunodeficiency syndrome	5.71e-05	0.000566	CcSEcCtD
Bosutinib—CSNK1E—lymph node—acquired immunodeficiency syndrome	5.7e-05	0.000681	CbGeAlD
Bosutinib—Nausea—Indinavir—acquired immunodeficiency syndrome	5.69e-05	0.000565	CcSEcCtD
Bosutinib—ERBB3—brain—acquired immunodeficiency syndrome	5.69e-05	0.00068	CbGeAlD
Bosutinib—Headache—Efavirenz—acquired immunodeficiency syndrome	5.67e-05	0.000563	CcSEcCtD
Bosutinib—ULK3—brain—acquired immunodeficiency syndrome	5.67e-05	0.000679	CbGeAlD
Bosutinib—MAP2K2—brain—acquired immunodeficiency syndrome	5.67e-05	0.000679	CbGeAlD
Bosutinib—Pruritus—Ritonavir—acquired immunodeficiency syndrome	5.67e-05	0.000562	CcSEcCtD
Bosutinib—MAP3K2—brain—acquired immunodeficiency syndrome	5.63e-05	0.000674	CbGeAlD
Bosutinib—SIK1—lymph node—acquired immunodeficiency syndrome	5.61e-05	0.000671	CbGeAlD
Bosutinib—IRAK4—lymph node—acquired immunodeficiency syndrome	5.61e-05	0.000671	CbGeAlD
Bosutinib—YES1—central nervous system—acquired immunodeficiency syndrome	5.59e-05	0.000669	CbGeAlD
Bosutinib—SRC—nervous system—acquired immunodeficiency syndrome	5.59e-05	0.000668	CbGeAlD
Bosutinib—MAP3K7—brain—acquired immunodeficiency syndrome	5.58e-05	0.000667	CbGeAlD
Bosutinib—EPHA4—lymph node—acquired immunodeficiency syndrome	5.55e-05	0.000664	CbGeAlD
Bosutinib—MAP2K5—lung—acquired immunodeficiency syndrome	5.55e-05	0.000664	CbGeAlD
Bosutinib—STK10—central nervous system—acquired immunodeficiency syndrome	5.54e-05	0.000662	CbGeAlD
Bosutinib—Asthenia—Saquinavir—acquired immunodeficiency syndrome	5.53e-05	0.000549	CcSEcCtD
Bosutinib—TAOK3—central nervous system—acquired immunodeficiency syndrome	5.52e-05	0.00066	CbGeAlD
Bosutinib—PTK2—brain—acquired immunodeficiency syndrome	5.52e-05	0.00066	CbGeAlD
Bosutinib—TBK1—brain—acquired immunodeficiency syndrome	5.52e-05	0.00066	CbGeAlD
Bosutinib—Vomiting—Delavirdine—acquired immunodeficiency syndrome	5.51e-05	0.000546	CcSEcCtD
Bosutinib—ERBB3—lymph node—acquired immunodeficiency syndrome	5.5e-05	0.000657	CbGeAlD
Bosutinib—Diarrhoea—Ritonavir—acquired immunodeficiency syndrome	5.48e-05	0.000544	CcSEcCtD
Bosutinib—MAP2K2—lymph node—acquired immunodeficiency syndrome	5.48e-05	0.000656	CbGeAlD
Bosutinib—ULK3—lymph node—acquired immunodeficiency syndrome	5.48e-05	0.000656	CbGeAlD
Bosutinib—PDGFRB—blood—acquired immunodeficiency syndrome	5.48e-05	0.000655	CbGeAlD
Bosutinib—Rash—Delavirdine—acquired immunodeficiency syndrome	5.46e-05	0.000542	CcSEcCtD
Bosutinib—Dermatitis—Delavirdine—acquired immunodeficiency syndrome	5.46e-05	0.000541	CcSEcCtD
Bosutinib—Pruritus—Saquinavir—acquired immunodeficiency syndrome	5.46e-05	0.000541	CcSEcCtD
Bosutinib—MAP3K2—lymph node—acquired immunodeficiency syndrome	5.44e-05	0.000651	CbGeAlD
Bosutinib—Headache—Delavirdine—acquired immunodeficiency syndrome	5.43e-05	0.000538	CcSEcCtD
Bosutinib—CSF1R—lung—acquired immunodeficiency syndrome	5.41e-05	0.000648	CbGeAlD
Bosutinib—IRAK1—brain—acquired immunodeficiency syndrome	5.41e-05	0.000647	CbGeAlD
Bosutinib—MAP3K7—lymph node—acquired immunodeficiency syndrome	5.39e-05	0.000645	CbGeAlD
Bosutinib—Nausea—Efavirenz—acquired immunodeficiency syndrome	5.38e-05	0.000533	CcSEcCtD
Bosutinib—SRC—central nervous system—acquired immunodeficiency syndrome	5.38e-05	0.000643	CbGeAlD
Bosutinib—PTK2—lymph node—acquired immunodeficiency syndrome	5.33e-05	0.000638	CbGeAlD
Bosutinib—TBK1—lymph node—acquired immunodeficiency syndrome	5.33e-05	0.000638	CbGeAlD
Bosutinib—RPS6KB1—brain—acquired immunodeficiency syndrome	5.31e-05	0.000635	CbGeAlD
Bosutinib—PDGFRB—bone marrow—acquired immunodeficiency syndrome	5.3e-05	0.000634	CbGeAlD
Bosutinib—Dizziness—Ritonavir—acquired immunodeficiency syndrome	5.3e-05	0.000525	CcSEcCtD
Bosutinib—Asthenia—Lamivudine—acquired immunodeficiency syndrome	5.28e-05	0.000523	CcSEcCtD
Bosutinib—Diarrhoea—Saquinavir—acquired immunodeficiency syndrome	5.28e-05	0.000523	CcSEcCtD
Bosutinib—PDGFRB—spinal cord—acquired immunodeficiency syndrome	5.28e-05	0.000631	CbGeAlD
Bosutinib—FGR—brain—acquired immunodeficiency syndrome	5.28e-05	0.000631	CbGeAlD
Bosutinib—AXL—brain—acquired immunodeficiency syndrome	5.25e-05	0.000628	CbGeAlD
Bosutinib—IRAK1—lymph node—acquired immunodeficiency syndrome	5.23e-05	0.000625	CbGeAlD
Bosutinib—Pruritus—Lamivudine—acquired immunodeficiency syndrome	5.21e-05	0.000516	CcSEcCtD
Bosutinib—ABL1—lymphoid tissue—acquired immunodeficiency syndrome	5.19e-05	0.000621	CbGeAlD
Bosutinib—Nausea—Delavirdine—acquired immunodeficiency syndrome	5.15e-05	0.00051	CcSEcCtD
Bosutinib—MAP2K5—nervous system—acquired immunodeficiency syndrome	5.14e-05	0.000614	CbGeAlD
Bosutinib—RPS6KB1—lymph node—acquired immunodeficiency syndrome	5.13e-05	0.000613	CbGeAlD
Bosutinib—ABL1—digestive system—acquired immunodeficiency syndrome	5.13e-05	0.000613	CbGeAlD
Bosutinib—Dizziness—Saquinavir—acquired immunodeficiency syndrome	5.1e-05	0.000506	CcSEcCtD
Bosutinib—LCK—lymph node—acquired immunodeficiency syndrome	5.1e-05	0.00061	CbGeAlD
Bosutinib—FGR—lymph node—acquired immunodeficiency syndrome	5.1e-05	0.00061	CbGeAlD
Bosutinib—Vomiting—Ritonavir—acquired immunodeficiency syndrome	5.1e-05	0.000505	CcSEcCtD
Bosutinib—PDGFRB—vagina—acquired immunodeficiency syndrome	5.08e-05	0.000607	CbGeAlD
Bosutinib—AXL—lymph node—acquired immunodeficiency syndrome	5.08e-05	0.000607	CbGeAlD
Bosutinib—SLK—brain—acquired immunodeficiency syndrome	5.06e-05	0.000605	CbGeAlD
Bosutinib—Rash—Ritonavir—acquired immunodeficiency syndrome	5.05e-05	0.000501	CcSEcCtD
Bosutinib—Dermatitis—Ritonavir—acquired immunodeficiency syndrome	5.05e-05	0.000501	CcSEcCtD
Bosutinib—Diarrhoea—Lamivudine—acquired immunodeficiency syndrome	5.04e-05	0.000499	CcSEcCtD
Bosutinib—EPHB4—brain—acquired immunodeficiency syndrome	5.02e-05	0.000601	CbGeAlD
Bosutinib—Headache—Ritonavir—acquired immunodeficiency syndrome	5.02e-05	0.000498	CcSEcCtD
Bosutinib—CSF1R—nervous system—acquired immunodeficiency syndrome	5.01e-05	0.0006	CbGeAlD
Bosutinib—MAP2K5—central nervous system—acquired immunodeficiency syndrome	4.95e-05	0.000592	CbGeAlD
Bosutinib—EPHA2—brain—acquired immunodeficiency syndrome	4.93e-05	0.000589	CbGeAlD
Bosutinib—FYN—brain—acquired immunodeficiency syndrome	4.92e-05	0.000588	CbGeAlD
Bosutinib—Vomiting—Saquinavir—acquired immunodeficiency syndrome	4.9e-05	0.000486	CcSEcCtD
Bosutinib—SLK—lymph node—acquired immunodeficiency syndrome	4.89e-05	0.000584	CbGeAlD
Bosutinib—ABL1—blood—acquired immunodeficiency syndrome	4.88e-05	0.000584	CbGeAlD
Bosutinib—Dizziness—Lamivudine—acquired immunodeficiency syndrome	4.87e-05	0.000482	CcSEcCtD
Bosutinib—Rash—Saquinavir—acquired immunodeficiency syndrome	4.86e-05	0.000482	CcSEcCtD
Bosutinib—Dermatitis—Saquinavir—acquired immunodeficiency syndrome	4.86e-05	0.000482	CcSEcCtD
Bosutinib—EPHB4—lymph node—acquired immunodeficiency syndrome	4.85e-05	0.00058	CbGeAlD
Bosutinib—Headache—Saquinavir—acquired immunodeficiency syndrome	4.83e-05	0.000479	CcSEcCtD
Bosutinib—CSF1R—central nervous system—acquired immunodeficiency syndrome	4.83e-05	0.000577	CbGeAlD
Bosutinib—MAP3K3—brain—acquired immunodeficiency syndrome	4.81e-05	0.000575	CbGeAlD
Bosutinib—MAP4K5—brain—acquired immunodeficiency syndrome	4.81e-05	0.000575	CbGeAlD
Bosutinib—PDGFRB—lung—acquired immunodeficiency syndrome	4.8e-05	0.000574	CbGeAlD
Bosutinib—Nausea—Ritonavir—acquired immunodeficiency syndrome	4.76e-05	0.000472	CcSEcCtD
Bosutinib—EPHA2—lymph node—acquired immunodeficiency syndrome	4.76e-05	0.000569	CbGeAlD
Bosutinib—FYN—lymph node—acquired immunodeficiency syndrome	4.75e-05	0.000568	CbGeAlD
Bosutinib—ABL1—bone marrow—acquired immunodeficiency syndrome	4.72e-05	0.000565	CbGeAlD
Bosutinib—ABL1—spinal cord—acquired immunodeficiency syndrome	4.7e-05	0.000563	CbGeAlD
Bosutinib—Vomiting—Lamivudine—acquired immunodeficiency syndrome	4.68e-05	0.000464	CcSEcCtD
Bosutinib—MAP4K5—lymph node—acquired immunodeficiency syndrome	4.64e-05	0.000555	CbGeAlD
Bosutinib—MAP3K3—lymph node—acquired immunodeficiency syndrome	4.64e-05	0.000555	CbGeAlD
Bosutinib—Rash—Lamivudine—acquired immunodeficiency syndrome	4.64e-05	0.00046	CcSEcCtD
Bosutinib—Dermatitis—Lamivudine—acquired immunodeficiency syndrome	4.64e-05	0.00046	CcSEcCtD
Bosutinib—Headache—Lamivudine—acquired immunodeficiency syndrome	4.61e-05	0.000457	CcSEcCtD
Bosutinib—Nausea—Saquinavir—acquired immunodeficiency syndrome	4.58e-05	0.000454	CcSEcCtD
Bosutinib—ABL1—vagina—acquired immunodeficiency syndrome	4.53e-05	0.000541	CbGeAlD
Bosutinib—PDGFRB—nervous system—acquired immunodeficiency syndrome	4.45e-05	0.000532	CbGeAlD
Bosutinib—YES1—brain—acquired immunodeficiency syndrome	4.44e-05	0.000531	CbGeAlD
Bosutinib—STK10—brain—acquired immunodeficiency syndrome	4.4e-05	0.000526	CbGeAlD
Bosutinib—TAOK3—brain—acquired immunodeficiency syndrome	4.38e-05	0.000524	CbGeAlD
Bosutinib—Nausea—Lamivudine—acquired immunodeficiency syndrome	4.37e-05	0.000433	CcSEcCtD
Bosutinib—YES1—lymph node—acquired immunodeficiency syndrome	4.29e-05	0.000513	CbGeAlD
Bosutinib—PDGFRB—central nervous system—acquired immunodeficiency syndrome	4.28e-05	0.000512	CbGeAlD
Bosutinib—ABL1—lung—acquired immunodeficiency syndrome	4.28e-05	0.000512	CbGeAlD
Bosutinib—SRC—brain—acquired immunodeficiency syndrome	4.27e-05	0.000511	CbGeAlD
Bosutinib—STK10—lymph node—acquired immunodeficiency syndrome	4.25e-05	0.000508	CbGeAlD
Bosutinib—TAOK3—lymph node—acquired immunodeficiency syndrome	4.23e-05	0.000506	CbGeAlD
Bosutinib—ABCB1—blood plasma—acquired immunodeficiency syndrome	4.14e-05	0.000496	CbGeAlD
Bosutinib—SRC—lymph node—acquired immunodeficiency syndrome	4.13e-05	0.000493	CbGeAlD
Bosutinib—ABL1—nervous system—acquired immunodeficiency syndrome	3.96e-05	0.000474	CbGeAlD
Bosutinib—MAP2K5—brain—acquired immunodeficiency syndrome	3.93e-05	0.00047	CbGeAlD
Bosutinib—CSF1R—brain—acquired immunodeficiency syndrome	3.83e-05	0.000458	CbGeAlD
Bosutinib—ABL1—central nervous system—acquired immunodeficiency syndrome	3.82e-05	0.000456	CbGeAlD
Bosutinib—MAP2K5—lymph node—acquired immunodeficiency syndrome	3.79e-05	0.000454	CbGeAlD
Bosutinib—CSF1R—lymph node—acquired immunodeficiency syndrome	3.7e-05	0.000443	CbGeAlD
Bosutinib—PDGFRB—brain—acquired immunodeficiency syndrome	3.4e-05	0.000407	CbGeAlD
Bosutinib—PDGFRB—lymph node—acquired immunodeficiency syndrome	3.28e-05	0.000393	CbGeAlD
Bosutinib—ABL1—brain—acquired immunodeficiency syndrome	3.03e-05	0.000362	CbGeAlD
Bosutinib—ABL1—lymph node—acquired immunodeficiency syndrome	2.93e-05	0.00035	CbGeAlD
Bosutinib—ABCB1—retina—acquired immunodeficiency syndrome	2.27e-05	0.000271	CbGeAlD
Bosutinib—CYP3A4—digestive system—acquired immunodeficiency syndrome	2.25e-05	0.000269	CbGeAlD
Bosutinib—CYP3A4—blood—acquired immunodeficiency syndrome	2.14e-05	0.000257	CbGeAlD
Bosutinib—CYP3A4—nervous system—acquired immunodeficiency syndrome	1.74e-05	0.000208	CbGeAlD
Bosutinib—CYP3A4—central nervous system—acquired immunodeficiency syndrome	1.68e-05	0.0002	CbGeAlD
Bosutinib—ABCB1—lymphoid tissue—acquired immunodeficiency syndrome	1.61e-05	0.000193	CbGeAlD
Bosutinib—ABCB1—digestive system—acquired immunodeficiency syndrome	1.59e-05	0.000191	CbGeAlD
Bosutinib—ABCB1—blood—acquired immunodeficiency syndrome	1.52e-05	0.000182	CbGeAlD
Bosutinib—ABCB1—bone marrow—acquired immunodeficiency syndrome	1.47e-05	0.000176	CbGeAlD
Bosutinib—ABCB1—spinal cord—acquired immunodeficiency syndrome	1.46e-05	0.000175	CbGeAlD
Bosutinib—ABCB1—vagina—acquired immunodeficiency syndrome	1.41e-05	0.000168	CbGeAlD
Bosutinib—ABCB1—lung—acquired immunodeficiency syndrome	1.33e-05	0.000159	CbGeAlD
Bosutinib—ABCB1—nervous system—acquired immunodeficiency syndrome	1.23e-05	0.000147	CbGeAlD
Bosutinib—ABCB1—central nervous system—acquired immunodeficiency syndrome	1.19e-05	0.000142	CbGeAlD
Bosutinib—ABCB1—brain—acquired immunodeficiency syndrome	9.42e-06	0.000113	CbGeAlD
Bosutinib—ABCB1—lymph node—acquired immunodeficiency syndrome	9.1e-06	0.000109	CbGeAlD
Bosutinib—LCK—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	3.71e-06	5.59e-05	CbGpPWpGaD
Bosutinib—FYN—Disease—CCR5—acquired immunodeficiency syndrome	3.71e-06	5.59e-05	CbGpPWpGaD
Bosutinib—LCK—Immune System—CD40LG—acquired immunodeficiency syndrome	3.7e-06	5.58e-05	CbGpPWpGaD
Bosutinib—MAP2K1—Axon guidance—IL6—acquired immunodeficiency syndrome	3.7e-06	5.57e-05	CbGpPWpGaD
Bosutinib—MAP2K1—Disease—CCR5—acquired immunodeficiency syndrome	3.69e-06	5.56e-05	CbGpPWpGaD
Bosutinib—LCK—Hemostasis—IL2—acquired immunodeficiency syndrome	3.69e-06	5.56e-05	CbGpPWpGaD
Bosutinib—IRAK1—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	3.67e-06	5.53e-05	CbGpPWpGaD
Bosutinib—PTK2—Developmental Biology—IL6—acquired immunodeficiency syndrome	3.66e-06	5.52e-05	CbGpPWpGaD
Bosutinib—LCK—Immune System—CD8A—acquired immunodeficiency syndrome	3.66e-06	5.51e-05	CbGpPWpGaD
Bosutinib—LCK—Immune System—CSF2—acquired immunodeficiency syndrome	3.66e-06	5.51e-05	CbGpPWpGaD
Bosutinib—CSK—Signaling Pathways—IL2—acquired immunodeficiency syndrome	3.65e-06	5.51e-05	CbGpPWpGaD
Bosutinib—EGFR—Immune System—HLA-B—acquired immunodeficiency syndrome	3.65e-06	5.5e-05	CbGpPWpGaD
Bosutinib—ERBB3—Innate Immune System—IL6—acquired immunodeficiency syndrome	3.64e-06	5.48e-05	CbGpPWpGaD
Bosutinib—ERBB3—Disease—CD4—acquired immunodeficiency syndrome	3.61e-06	5.45e-05	CbGpPWpGaD
Bosutinib—YES1—Developmental Biology—IL6—acquired immunodeficiency syndrome	3.61e-06	5.45e-05	CbGpPWpGaD
Bosutinib—PTK2—Immune System—IFNG—acquired immunodeficiency syndrome	3.61e-06	5.44e-05	CbGpPWpGaD
Bosutinib—LCK—Innate Immune System—CD4—acquired immunodeficiency syndrome	3.61e-06	5.44e-05	CbGpPWpGaD
Bosutinib—ERBB3—Immune System—IL2—acquired immunodeficiency syndrome	3.6e-06	5.43e-05	CbGpPWpGaD
Bosutinib—EGFR—Adaptive Immune System—CD4—acquired immunodeficiency syndrome	3.59e-06	5.42e-05	CbGpPWpGaD
Bosutinib—PTK2—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	3.59e-06	5.41e-05	CbGpPWpGaD
Bosutinib—YES1—Immune System—IFNG—acquired immunodeficiency syndrome	3.56e-06	5.37e-05	CbGpPWpGaD
Bosutinib—EGFR—Signaling by NGF—IL6—acquired immunodeficiency syndrome	3.55e-06	5.35e-05	CbGpPWpGaD
Bosutinib—YES1—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	3.54e-06	5.33e-05	CbGpPWpGaD
Bosutinib—LCK—Immune System—HLA-B—acquired immunodeficiency syndrome	3.52e-06	5.3e-05	CbGpPWpGaD
Bosutinib—FER—Signaling Pathways—IL6—acquired immunodeficiency syndrome	3.52e-06	5.3e-05	CbGpPWpGaD
Bosutinib—MAP3K7—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	3.51e-06	5.29e-05	CbGpPWpGaD
Bosutinib—SYK—Immune System—IL6—acquired immunodeficiency syndrome	3.5e-06	5.28e-05	CbGpPWpGaD
Bosutinib—MAP2K2—Developmental Biology—TNF—acquired immunodeficiency syndrome	3.49e-06	5.27e-05	CbGpPWpGaD
Bosutinib—PTK2—Immune System—CD4—acquired immunodeficiency syndrome	3.48e-06	5.25e-05	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	3.48e-06	5.25e-05	CbGpPWpGaD
Bosutinib—LCK—Cytokine Signaling in Immune system—IL6—acquired immunodeficiency syndrome	3.48e-06	5.24e-05	CbGpPWpGaD
Bosutinib—LCK—Adaptive Immune System—CD4—acquired immunodeficiency syndrome	3.46e-06	5.22e-05	CbGpPWpGaD
Bosutinib—MAP3K7—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	3.45e-06	5.21e-05	CbGpPWpGaD
Bosutinib—PRKCQ—Immune System—IL6—acquired immunodeficiency syndrome	3.44e-06	5.19e-05	CbGpPWpGaD
Bosutinib—YES1—Immune System—CD4—acquired immunodeficiency syndrome	3.44e-06	5.18e-05	CbGpPWpGaD
Bosutinib—LCK—Signaling by NGF—IL6—acquired immunodeficiency syndrome	3.42e-06	5.16e-05	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—TAT—acquired immunodeficiency syndrome	3.41e-06	5.14e-05	CbGpPWpGaD
Bosutinib—IRAK1—Immune System—IFNG—acquired immunodeficiency syndrome	3.37e-06	5.09e-05	CbGpPWpGaD
Bosutinib—IRAK1—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	3.36e-06	5.06e-05	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	3.36e-06	5.06e-05	CbGpPWpGaD
Bosutinib—LYN—Developmental Biology—TNF—acquired immunodeficiency syndrome	3.34e-06	5.03e-05	CbGpPWpGaD
Bosutinib—AXL—Signaling Pathways—IL6—acquired immunodeficiency syndrome	3.33e-06	5.03e-05	CbGpPWpGaD
Bosutinib—ABL1—Developmental Biology—TNF—acquired immunodeficiency syndrome	3.32e-06	5.01e-05	CbGpPWpGaD
Bosutinib—CSK—Immune System—IL6—acquired immunodeficiency syndrome	3.32e-06	5.01e-05	CbGpPWpGaD
Bosutinib—FYN—Developmental Biology—TNF—acquired immunodeficiency syndrome	3.29e-06	4.96e-05	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	3.29e-06	4.95e-05	CbGpPWpGaD
Bosutinib—SRC—Immune System—CD40LG—acquired immunodeficiency syndrome	3.27e-06	4.94e-05	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	3.27e-06	4.94e-05	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	3.27e-06	4.94e-05	CbGpPWpGaD
Bosutinib—MAP2K1—Developmental Biology—TNF—acquired immunodeficiency syndrome	3.27e-06	4.93e-05	CbGpPWpGaD
Bosutinib—SRC—Hemostasis—IL2—acquired immunodeficiency syndrome	3.26e-06	4.92e-05	CbGpPWpGaD
Bosutinib—IRAK1—Immune System—CD4—acquired immunodeficiency syndrome	3.26e-06	4.91e-05	CbGpPWpGaD
Bosutinib—SRC—Immune System—CD8A—acquired immunodeficiency syndrome	3.24e-06	4.88e-05	CbGpPWpGaD
Bosutinib—SRC—Immune System—CSF2—acquired immunodeficiency syndrome	3.24e-06	4.88e-05	CbGpPWpGaD
Bosutinib—PTK2—Innate Immune System—IL6—acquired immunodeficiency syndrome	3.24e-06	4.88e-05	CbGpPWpGaD
Bosutinib—EGFR—Axon guidance—IL6—acquired immunodeficiency syndrome	3.21e-06	4.84e-05	CbGpPWpGaD
Bosutinib—PTK2—Immune System—IL2—acquired immunodeficiency syndrome	3.21e-06	4.83e-05	CbGpPWpGaD
Bosutinib—EGFR—Disease—CCR5—acquired immunodeficiency syndrome	3.2e-06	4.83e-05	CbGpPWpGaD
Bosutinib—SRC—Innate Immune System—CD4—acquired immunodeficiency syndrome	3.19e-06	4.81e-05	CbGpPWpGaD
Bosutinib—YES1—Innate Immune System—IL6—acquired immunodeficiency syndrome	3.19e-06	4.81e-05	CbGpPWpGaD
Bosutinib—BMPR2—Signaling Pathways—IL6—acquired immunodeficiency syndrome	3.18e-06	4.79e-05	CbGpPWpGaD
Bosutinib—MAP3K7—Immune System—IFNG—acquired immunodeficiency syndrome	3.18e-06	4.79e-05	CbGpPWpGaD
Bosutinib—PRKCQ—Disease—IL6—acquired immunodeficiency syndrome	3.18e-06	4.79e-05	CbGpPWpGaD
Bosutinib—CSNK1A1—Disease—IL6—acquired immunodeficiency syndrome	3.18e-06	4.79e-05	CbGpPWpGaD
Bosutinib—YES1—Immune System—IL2—acquired immunodeficiency syndrome	3.16e-06	4.77e-05	CbGpPWpGaD
Bosutinib—MAP3K7—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	3.16e-06	4.76e-05	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	3.16e-06	4.76e-05	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	3.16e-06	4.76e-05	CbGpPWpGaD
Bosutinib—SRC—Immune System—HLA-B—acquired immunodeficiency syndrome	3.11e-06	4.7e-05	CbGpPWpGaD
Bosutinib—LCK—Disease—CCR5—acquired immunodeficiency syndrome	3.09e-06	4.66e-05	CbGpPWpGaD
Bosutinib—MAP3K7—Immune System—CD4—acquired immunodeficiency syndrome	3.07e-06	4.63e-05	CbGpPWpGaD
Bosutinib—CSK—Disease—IL6—acquired immunodeficiency syndrome	3.07e-06	4.62e-05	CbGpPWpGaD
Bosutinib—SRC—Adaptive Immune System—CD4—acquired immunodeficiency syndrome	3.07e-06	4.62e-05	CbGpPWpGaD
Bosutinib—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—acquired immunodeficiency syndrome	3.07e-06	4.62e-05	CbGpPWpGaD
Bosutinib—MAP2K2—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	3.07e-06	4.62e-05	CbGpPWpGaD
Bosutinib—CSNK1E—Signaling Pathways—IL2—acquired immunodeficiency syndrome	3.06e-06	4.61e-05	CbGpPWpGaD
Bosutinib—BCR—Signaling Pathways—IL6—acquired immunodeficiency syndrome	3.05e-06	4.6e-05	CbGpPWpGaD
Bosutinib—SRC—Signaling by NGF—IL6—acquired immunodeficiency syndrome	3.03e-06	4.56e-05	CbGpPWpGaD
Bosutinib—IRAK1—Innate Immune System—IL6—acquired immunodeficiency syndrome	3.03e-06	4.56e-05	CbGpPWpGaD
Bosutinib—MAP2K2—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	3.02e-06	4.55e-05	CbGpPWpGaD
Bosutinib—IRAK1—Immune System—IL2—acquired immunodeficiency syndrome	3e-06	4.52e-05	CbGpPWpGaD
Bosutinib—PDGFRB—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	2.99e-06	4.51e-05	CbGpPWpGaD
Bosutinib—TBK1—Immune System—IL6—acquired immunodeficiency syndrome	2.98e-06	4.49e-05	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	2.97e-06	4.48e-05	CbGpPWpGaD
Bosutinib—PDGFRB—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	2.95e-06	4.44e-05	CbGpPWpGaD
Bosutinib—LYN—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	2.93e-06	4.42e-05	CbGpPWpGaD
Bosutinib—CAMK2G—Immune System—IL6—acquired immunodeficiency syndrome	2.92e-06	4.41e-05	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—AGPS—acquired immunodeficiency syndrome	2.9e-06	4.37e-05	CbGpPWpGaD
Bosutinib—LYN—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	2.88e-06	4.35e-05	CbGpPWpGaD
Bosutinib—FYN—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	2.88e-06	4.35e-05	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	2.87e-06	4.32e-05	CbGpPWpGaD
Bosutinib—MAP3K3—Immune System—IL6—acquired immunodeficiency syndrome	2.86e-06	4.31e-05	CbGpPWpGaD
Bosutinib—MAP3K7—Innate Immune System—IL6—acquired immunodeficiency syndrome	2.85e-06	4.3e-05	CbGpPWpGaD
Bosutinib—FYN—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	2.84e-06	4.28e-05	CbGpPWpGaD
Bosutinib—EGFR—Developmental Biology—TNF—acquired immunodeficiency syndrome	2.84e-06	4.28e-05	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	2.82e-06	4.26e-05	CbGpPWpGaD
Bosutinib—MAP3K7—Immune System—IL2—acquired immunodeficiency syndrome	2.82e-06	4.26e-05	CbGpPWpGaD
Bosutinib—MAP2K2—Developmental Biology—IL6—acquired immunodeficiency syndrome	2.82e-06	4.25e-05	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	2.79e-06	4.21e-05	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	2.79e-06	4.21e-05	CbGpPWpGaD
Bosutinib—BTK—Immune System—IL6—acquired immunodeficiency syndrome	2.78e-06	4.19e-05	CbGpPWpGaD
Bosutinib—MAP2K2—Immune System—IFNG—acquired immunodeficiency syndrome	2.78e-06	4.19e-05	CbGpPWpGaD
Bosutinib—MAP2K2—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	2.76e-06	4.16e-05	CbGpPWpGaD
Bosutinib—SRC—Axon guidance—IL6—acquired immunodeficiency syndrome	2.74e-06	4.13e-05	CbGpPWpGaD
Bosutinib—SRC—Disease—CCR5—acquired immunodeficiency syndrome	2.73e-06	4.12e-05	CbGpPWpGaD
Bosutinib—PDGFRB—Immune System—IFNG—acquired immunodeficiency syndrome	2.71e-06	4.09e-05	CbGpPWpGaD
Bosutinib—MAP2K2—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	2.7e-06	4.07e-05	CbGpPWpGaD
Bosutinib—PDGFRB—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	2.69e-06	4.06e-05	CbGpPWpGaD
Bosutinib—LYN—Developmental Biology—IL6—acquired immunodeficiency syndrome	2.69e-06	4.06e-05	CbGpPWpGaD
Bosutinib—MAP2K2—Immune System—CD4—acquired immunodeficiency syndrome	2.68e-06	4.04e-05	CbGpPWpGaD
Bosutinib—ABL1—Developmental Biology—IL6—acquired immunodeficiency syndrome	2.68e-06	4.04e-05	CbGpPWpGaD
Bosutinib—FES—Signaling Pathways—IL6—acquired immunodeficiency syndrome	2.66e-06	4.02e-05	CbGpPWpGaD
Bosutinib—IRAK4—Immune System—IL6—acquired immunodeficiency syndrome	2.66e-06	4e-05	CbGpPWpGaD
Bosutinib—LYN—Immune System—IFNG—acquired immunodeficiency syndrome	2.65e-06	4e-05	CbGpPWpGaD
Bosutinib—FYN—Developmental Biology—IL6—acquired immunodeficiency syndrome	2.65e-06	4e-05	CbGpPWpGaD
Bosutinib—ERBB4—Signaling Pathways—IL2—acquired immunodeficiency syndrome	2.64e-06	3.98e-05	CbGpPWpGaD
Bosutinib—ABL1—Immune System—IFNG—acquired immunodeficiency syndrome	2.64e-06	3.98e-05	CbGpPWpGaD
Bosutinib—LYN—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	2.64e-06	3.98e-05	CbGpPWpGaD
Bosutinib—MAP2K1—Developmental Biology—IL6—acquired immunodeficiency syndrome	2.64e-06	3.98e-05	CbGpPWpGaD
Bosutinib—PDGFRB—Immune System—CD4—acquired immunodeficiency syndrome	2.62e-06	3.95e-05	CbGpPWpGaD
Bosutinib—FYN—Immune System—IFNG—acquired immunodeficiency syndrome	2.61e-06	3.94e-05	CbGpPWpGaD
Bosutinib—PTK2B—Signaling Pathways—IL2—acquired immunodeficiency syndrome	2.6e-06	3.93e-05	CbGpPWpGaD
Bosutinib—MAP2K1—Immune System—IFNG—acquired immunodeficiency syndrome	2.6e-06	3.92e-05	CbGpPWpGaD
Bosutinib—FYN—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	2.6e-06	3.92e-05	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	2.58e-06	3.9e-05	CbGpPWpGaD
Bosutinib—CSNK1E—Disease—IL6—acquired immunodeficiency syndrome	2.57e-06	3.87e-05	CbGpPWpGaD
Bosutinib—LYN—Immune System—CD4—acquired immunodeficiency syndrome	2.56e-06	3.86e-05	CbGpPWpGaD
Bosutinib—ABL1—Immune System—CD4—acquired immunodeficiency syndrome	2.55e-06	3.85e-05	CbGpPWpGaD
Bosutinib—HCK—Immune System—IL6—acquired immunodeficiency syndrome	2.55e-06	3.84e-05	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	2.53e-06	3.81e-05	CbGpPWpGaD
Bosutinib—FYN—Immune System—CD4—acquired immunodeficiency syndrome	2.52e-06	3.8e-05	CbGpPWpGaD
Bosutinib—MAP2K1—Immune System—CD4—acquired immunodeficiency syndrome	2.51e-06	3.78e-05	CbGpPWpGaD
Bosutinib—ROCK1—Signaling Pathways—IL2—acquired immunodeficiency syndrome	2.51e-06	3.78e-05	CbGpPWpGaD
Bosutinib—ROCK1—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	2.5e-06	3.76e-05	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	2.49e-06	3.76e-05	CbGpPWpGaD
Bosutinib—MAP2K2—Innate Immune System—IL6—acquired immunodeficiency syndrome	2.49e-06	3.75e-05	CbGpPWpGaD
Bosutinib—MAP2K2—Disease—CD4—acquired immunodeficiency syndrome	2.48e-06	3.73e-05	CbGpPWpGaD
Bosutinib—MAP2K2—Immune System—IL2—acquired immunodeficiency syndrome	2.47e-06	3.72e-05	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	2.45e-06	3.7e-05	CbGpPWpGaD
Bosutinib—PDGFRB—Innate Immune System—IL6—acquired immunodeficiency syndrome	2.43e-06	3.66e-05	CbGpPWpGaD
Bosutinib—SRC—Developmental Biology—TNF—acquired immunodeficiency syndrome	2.42e-06	3.65e-05	CbGpPWpGaD
Bosutinib—PDGFRB—Disease—CD4—acquired immunodeficiency syndrome	2.42e-06	3.64e-05	CbGpPWpGaD
Bosutinib—RPS6KB1—Signaling Pathways—IL2—acquired immunodeficiency syndrome	2.42e-06	3.64e-05	CbGpPWpGaD
Bosutinib—MAP2K5—Signaling Pathways—IL2—acquired immunodeficiency syndrome	2.42e-06	3.64e-05	CbGpPWpGaD
Bosutinib—PDGFRB—Immune System—IL2—acquired immunodeficiency syndrome	2.41e-06	3.63e-05	CbGpPWpGaD
Bosutinib—ERBB4—Immune System—IL6—acquired immunodeficiency syndrome	2.4e-06	3.62e-05	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	2.4e-06	3.62e-05	CbGpPWpGaD
Bosutinib—LYN—Innate Immune System—IL6—acquired immunodeficiency syndrome	2.38e-06	3.59e-05	CbGpPWpGaD
Bosutinib—ABL1—Innate Immune System—IL6—acquired immunodeficiency syndrome	2.37e-06	3.57e-05	CbGpPWpGaD
Bosutinib—PTK2B—Immune System—IL6—acquired immunodeficiency syndrome	2.37e-06	3.57e-05	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	2.36e-06	3.56e-05	CbGpPWpGaD
Bosutinib—LYN—Immune System—IL2—acquired immunodeficiency syndrome	2.36e-06	3.55e-05	CbGpPWpGaD
Bosutinib—HCK—Disease—IL6—acquired immunodeficiency syndrome	2.35e-06	3.55e-05	CbGpPWpGaD
Bosutinib—ABL1—Immune System—IL2—acquired immunodeficiency syndrome	2.35e-06	3.54e-05	CbGpPWpGaD
Bosutinib—FYN—Innate Immune System—IL6—acquired immunodeficiency syndrome	2.34e-06	3.53e-05	CbGpPWpGaD
Bosutinib—MAP2K1—Innate Immune System—IL6—acquired immunodeficiency syndrome	2.33e-06	3.51e-05	CbGpPWpGaD
Bosutinib—FYN—Disease—CD4—acquired immunodeficiency syndrome	2.33e-06	3.51e-05	CbGpPWpGaD
Bosutinib—ERBB3—Signaling Pathways—IL2—acquired immunodeficiency syndrome	2.33e-06	3.51e-05	CbGpPWpGaD
Bosutinib—FYN—Immune System—IL2—acquired immunodeficiency syndrome	2.32e-06	3.5e-05	CbGpPWpGaD
Bosutinib—MAP2K1—Disease—CD4—acquired immunodeficiency syndrome	2.32e-06	3.49e-05	CbGpPWpGaD
Bosutinib—BLK—Immune System—IL6—acquired immunodeficiency syndrome	2.31e-06	3.48e-05	CbGpPWpGaD
Bosutinib—MAP2K1—Immune System—IL2—acquired immunodeficiency syndrome	2.31e-06	3.48e-05	CbGpPWpGaD
Bosutinib—FGR—Immune System—IL6—acquired immunodeficiency syndrome	2.3e-06	3.47e-05	CbGpPWpGaD
Bosutinib—EGFR—Developmental Biology—IL6—acquired immunodeficiency syndrome	2.29e-06	3.45e-05	CbGpPWpGaD
Bosutinib—SYK—Signaling Pathways—IL6—acquired immunodeficiency syndrome	2.27e-06	3.42e-05	CbGpPWpGaD
Bosutinib—EGFR—Immune System—IFNG—acquired immunodeficiency syndrome	2.26e-06	3.4e-05	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	2.24e-06	3.38e-05	CbGpPWpGaD
Bosutinib—PRKCQ—Signaling Pathways—IL6—acquired immunodeficiency syndrome	2.22e-06	3.35e-05	CbGpPWpGaD
Bosutinib—CSNK1A1—Signaling Pathways—IL6—acquired immunodeficiency syndrome	2.22e-06	3.35e-05	CbGpPWpGaD
Bosutinib—ERBB4—Disease—IL6—acquired immunodeficiency syndrome	2.22e-06	3.34e-05	CbGpPWpGaD
Bosutinib—EGFR—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	2.19e-06	3.31e-05	CbGpPWpGaD
Bosutinib—EGFR—Immune System—CD4—acquired immunodeficiency syndrome	2.18e-06	3.29e-05	CbGpPWpGaD
Bosutinib—LCK—Immune System—IFNG—acquired immunodeficiency syndrome	2.17e-06	3.28e-05	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	2.16e-06	3.26e-05	CbGpPWpGaD
Bosutinib—CSK—Signaling Pathways—IL6—acquired immunodeficiency syndrome	2.15e-06	3.24e-05	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	2.12e-06	3.2e-05	CbGpPWpGaD
Bosutinib—ERBB3—Immune System—IL6—acquired immunodeficiency syndrome	2.12e-06	3.19e-05	CbGpPWpGaD
Bosutinib—LCK—Immune System—CD4—acquired immunodeficiency syndrome	2.1e-06	3.17e-05	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	2.09e-06	3.16e-05	CbGpPWpGaD
Bosutinib—PTK2—Signaling Pathways—IL2—acquired immunodeficiency syndrome	2.07e-06	3.13e-05	CbGpPWpGaD
Bosutinib—ABCB1—Transmembrane transport of small molecules—ALB—acquired immunodeficiency syndrome	2.06e-06	3.11e-05	CbGpPWpGaD
Bosutinib—YES1—Signaling Pathways—IL2—acquired immunodeficiency syndrome	2.04e-06	3.08e-05	CbGpPWpGaD
Bosutinib—EGFR—Innate Immune System—IL6—acquired immunodeficiency syndrome	2.02e-06	3.05e-05	CbGpPWpGaD
Bosutinib—EGFR—Disease—CD4—acquired immunodeficiency syndrome	2.01e-06	3.03e-05	CbGpPWpGaD
Bosutinib—EGFR—Immune System—IL2—acquired immunodeficiency syndrome	2.01e-06	3.02e-05	CbGpPWpGaD
Bosutinib—SRC—Developmental Biology—IL6—acquired immunodeficiency syndrome	1.95e-06	2.95e-05	CbGpPWpGaD
Bosutinib—ERBB3—Disease—IL6—acquired immunodeficiency syndrome	1.95e-06	2.95e-05	CbGpPWpGaD
Bosutinib—LCK—Innate Immune System—IL6—acquired immunodeficiency syndrome	1.95e-06	2.94e-05	CbGpPWpGaD
Bosutinib—LCK—Disease—CD4—acquired immunodeficiency syndrome	1.94e-06	2.92e-05	CbGpPWpGaD
Bosutinib—IRAK1—Signaling Pathways—IL2—acquired immunodeficiency syndrome	1.94e-06	2.92e-05	CbGpPWpGaD
Bosutinib—LCK—Immune System—IL2—acquired immunodeficiency syndrome	1.93e-06	2.91e-05	CbGpPWpGaD
Bosutinib—SRC—Immune System—IFNG—acquired immunodeficiency syndrome	1.93e-06	2.9e-05	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	1.91e-06	2.89e-05	CbGpPWpGaD
Bosutinib—PTK2—Immune System—IL6—acquired immunodeficiency syndrome	1.88e-06	2.84e-05	CbGpPWpGaD
Bosutinib—SRC—Immune System—CD4—acquired immunodeficiency syndrome	1.86e-06	2.8e-05	CbGpPWpGaD
Bosutinib—YES1—Immune System—IL6—acquired immunodeficiency syndrome	1.86e-06	2.8e-05	CbGpPWpGaD
Bosutinib—MAP3K7—Signaling Pathways—IL2—acquired immunodeficiency syndrome	1.83e-06	2.75e-05	CbGpPWpGaD
Bosutinib—CSNK1E—Signaling Pathways—IL6—acquired immunodeficiency syndrome	1.8e-06	2.71e-05	CbGpPWpGaD
Bosutinib—IRAK1—Immune System—IL6—acquired immunodeficiency syndrome	1.76e-06	2.66e-05	CbGpPWpGaD
Bosutinib—SRC—Innate Immune System—IL6—acquired immunodeficiency syndrome	1.73e-06	2.6e-05	CbGpPWpGaD
Bosutinib—SRC—Disease—CD4—acquired immunodeficiency syndrome	1.72e-06	2.59e-05	CbGpPWpGaD
Bosutinib—SRC—Immune System—IL2—acquired immunodeficiency syndrome	1.71e-06	2.58e-05	CbGpPWpGaD
Bosutinib—MAP3K7—Immune System—IL6—acquired immunodeficiency syndrome	1.66e-06	2.5e-05	CbGpPWpGaD
Bosutinib—MAP2K2—Signaling Pathways—IL2—acquired immunodeficiency syndrome	1.6e-06	2.41e-05	CbGpPWpGaD
Bosutinib—MAP2K2—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	1.59e-06	2.39e-05	CbGpPWpGaD
Bosutinib—PDGFRB—Signaling Pathways—IL2—acquired immunodeficiency syndrome	1.56e-06	2.35e-05	CbGpPWpGaD
Bosutinib—ERBB4—Signaling Pathways—IL6—acquired immunodeficiency syndrome	1.55e-06	2.34e-05	CbGpPWpGaD
Bosutinib—PTK2B—Signaling Pathways—IL6—acquired immunodeficiency syndrome	1.53e-06	2.31e-05	CbGpPWpGaD
Bosutinib—LYN—Signaling Pathways—IL2—acquired immunodeficiency syndrome	1.52e-06	2.3e-05	CbGpPWpGaD
Bosutinib—FYN—Signaling Pathways—IL2—acquired immunodeficiency syndrome	1.5e-06	2.26e-05	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling Pathways—IL2—acquired immunodeficiency syndrome	1.49e-06	2.25e-05	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	1.49e-06	2.24e-05	CbGpPWpGaD
Bosutinib—ROCK1—Signaling Pathways—IL6—acquired immunodeficiency syndrome	1.47e-06	2.22e-05	CbGpPWpGaD
Bosutinib—MAP2K2—Immune System—IL6—acquired immunodeficiency syndrome	1.45e-06	2.19e-05	CbGpPWpGaD
Bosutinib—RPS6KB1—Signaling Pathways—IL6—acquired immunodeficiency syndrome	1.42e-06	2.14e-05	CbGpPWpGaD
Bosutinib—MAP2K5—Signaling Pathways—IL6—acquired immunodeficiency syndrome	1.42e-06	2.14e-05	CbGpPWpGaD
Bosutinib—PDGFRB—Immune System—IL6—acquired immunodeficiency syndrome	1.42e-06	2.13e-05	CbGpPWpGaD
Bosutinib—LYN—Immune System—IL6—acquired immunodeficiency syndrome	1.39e-06	2.09e-05	CbGpPWpGaD
Bosutinib—ABL1—Immune System—IL6—acquired immunodeficiency syndrome	1.38e-06	2.08e-05	CbGpPWpGaD
Bosutinib—ERBB3—Signaling Pathways—IL6—acquired immunodeficiency syndrome	1.37e-06	2.06e-05	CbGpPWpGaD
Bosutinib—FYN—Immune System—IL6—acquired immunodeficiency syndrome	1.36e-06	2.06e-05	CbGpPWpGaD
Bosutinib—MAP2K1—Immune System—IL6—acquired immunodeficiency syndrome	1.36e-06	2.05e-05	CbGpPWpGaD
Bosutinib—MAP2K2—Disease—IL6—acquired immunodeficiency syndrome	1.34e-06	2.02e-05	CbGpPWpGaD
Bosutinib—PDGFRB—Disease—IL6—acquired immunodeficiency syndrome	1.31e-06	1.97e-05	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—IL2—acquired immunodeficiency syndrome	1.3e-06	1.95e-05	CbGpPWpGaD
Bosutinib—EGFR—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	1.29e-06	1.95e-05	CbGpPWpGaD
Bosutinib—FYN—Disease—IL6—acquired immunodeficiency syndrome	1.26e-06	1.9e-05	CbGpPWpGaD
Bosutinib—MAP2K1—Disease—IL6—acquired immunodeficiency syndrome	1.25e-06	1.89e-05	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—IL2—acquired immunodeficiency syndrome	1.25e-06	1.88e-05	CbGpPWpGaD
Bosutinib—PTK2—Signaling Pathways—IL6—acquired immunodeficiency syndrome	1.22e-06	1.84e-05	CbGpPWpGaD
Bosutinib—YES1—Signaling Pathways—IL6—acquired immunodeficiency syndrome	1.2e-06	1.81e-05	CbGpPWpGaD
Bosutinib—EGFR—Immune System—IL6—acquired immunodeficiency syndrome	1.18e-06	1.78e-05	CbGpPWpGaD
Bosutinib—IRAK1—Signaling Pathways—IL6—acquired immunodeficiency syndrome	1.14e-06	1.72e-05	CbGpPWpGaD
Bosutinib—LCK—Immune System—IL6—acquired immunodeficiency syndrome	1.14e-06	1.71e-05	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—IL2—acquired immunodeficiency syndrome	1.11e-06	1.67e-05	CbGpPWpGaD
Bosutinib—EGFR—Disease—IL6—acquired immunodeficiency syndrome	1.09e-06	1.64e-05	CbGpPWpGaD
Bosutinib—MAP3K7—Signaling Pathways—IL6—acquired immunodeficiency syndrome	1.07e-06	1.62e-05	CbGpPWpGaD
Bosutinib—LCK—Disease—IL6—acquired immunodeficiency syndrome	1.05e-06	1.58e-05	CbGpPWpGaD
Bosutinib—SRC—Immune System—IL6—acquired immunodeficiency syndrome	1.01e-06	1.52e-05	CbGpPWpGaD
Bosutinib—ABCB1—Metabolism—ALB—acquired immunodeficiency syndrome	9.65e-07	1.46e-05	CbGpPWpGaD
Bosutinib—MAP2K2—Signaling Pathways—IL6—acquired immunodeficiency syndrome	9.38e-07	1.41e-05	CbGpPWpGaD
Bosutinib—SRC—Disease—IL6—acquired immunodeficiency syndrome	9.28e-07	1.4e-05	CbGpPWpGaD
Bosutinib—PDGFRB—Signaling Pathways—IL6—acquired immunodeficiency syndrome	9.15e-07	1.38e-05	CbGpPWpGaD
Bosutinib—LYN—Signaling Pathways—IL6—acquired immunodeficiency syndrome	8.96e-07	1.35e-05	CbGpPWpGaD
Bosutinib—FYN—Signaling Pathways—IL6—acquired immunodeficiency syndrome	8.82e-07	1.33e-05	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling Pathways—IL6—acquired immunodeficiency syndrome	8.77e-07	1.32e-05	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—IL6—acquired immunodeficiency syndrome	7.62e-07	1.15e-05	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—IL6—acquired immunodeficiency syndrome	7.34e-07	1.11e-05	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—IL6—acquired immunodeficiency syndrome	6.5e-07	9.8e-06	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—ALB—acquired immunodeficiency syndrome	5.95e-07	8.97e-06	CbGpPWpGaD
